

15h05 **Evaluation of post-transplant cellular therapy outcomes**

Anna Sureda (Barcelona, ESP)

- Diagnosis and management of HPC graft failure
- Evaluation of late effects of allogeneic and autologous transplants, including cellular, pharmacologic, and radiation therapy
- Documentation and reporting for patients on investigational protocols
- Applicable regulations and reporting responsibilities for adverse events

15h45 Coffee/tea break

16h05 **Identification, evaluation, and selection of HPC source, including use of donor registries**

Jakob Passweg (Basel, CH)

- Donor eligibility determination
- Methodology and implications of human leukocyte antigen (HLA) typing
- Administration of ABO incompatible cellular therapy products and management of patients
- Donor rights, confidentiality and privacy

16h45 Questions and Answers with all speakers

17h15 Closing remarks

FREE REGISTRATION -
LIMITED ACCESS REGISTRATION AT:
<https://ebmt.stagehq.com/events/3699>



Istituto Oncologico della Svizzera Italiana – Oncology Institute of Southern Switzerland

Transplant Procedures Update for Physicians and Nurses operating in JACIE accredited transplant centers Focus on Competency Maintenance

September 16th 2016
Regional Hospital of Bellinzona (San Giovanni)
Auditorium
From 8h30 to 17h15



Program

8h30	Registration and coffee		
9h00	Welcome message and objectives Luciano Wannesson (Bellinzona, CH) Overview of JACIE process and implications Aleksandra Babic (Bellinzona, CH)		
9h15	Indications for HPC transplantation Luciano Wannesson (Bellinzona, CH) Georg Stüssi (Bellinzona, CH) Autologous Luciano Wannesson Standard indications – An Update <ul style="list-style-type: none">– Experimental indications.– High-dose regimens Allogeneic Georg Stüssi <ul style="list-style-type: none">– Standard indications – An Update– Experimental indications– Preparative regimens (TBI including): myeloablative, RIC, haplo	12h00	
9h55	Care of immunocompromised patients Michelle Kenyon (London, UK) <ul style="list-style-type: none">– Hematology/oncology patient care, including an overview of the cellular therapy process– Administration of preparative regimens, blood products, cellular therapy products, and other supportive therapies– HPC product infusion and patient management– Recognition of cellular therapy complications and emergencies requiring rapid notification of the transplant team	12h40	
10h40	Coffee break	12h55	
11h00	Early and acute complications in BMT setting, diagnosis and management Simone Cesaro (Verona, IT) Elisabeth Wallhult (Goeteborg, SE) Arno Mank (Amsterdam, NL)	13h45	
			<ul style="list-style-type: none">– Management of mucositis, nausea, vomiting and pain management - A. M.– Central venous access device, care neutropenic fever, management of thrombocytopenia and bleeding - A. M.– Management of hemorrhagic cystitis - E. W.– Diagnosis and management of veno-occlusive disease of the liver - E. W.– Respiratory infections - S. C.– Fungal infections - S. C.– Common viral complications - S. C.– Multi-resistant bacteria - reducing the spread - S. C.
			Supportive care of the HSCT recipient Caroline Bompont (Monpellier, FR) <ul style="list-style-type: none">– Principles of nutritional support– Psychological care: Meeting information needs– Survivorship and quality of life– Palliative and end of life care: pain management
			Questions and Answers with all speakers
			Lunch
			Cell source and Apheresis Francesco Lanza (Ravenna, IT) <ul style="list-style-type: none">– Administration of growth factors for HPC mobilization and for posttransplant hematopoietic cell reconstitution– HPC processing: principles of bone marrow harvest procedures and apheresis collection procedures– New CB application– HPC cryopreservation– Extracorporeal photopheresis for GVHD
			Graft versus Host Disease (GvHD) Mats Brune (Göteborg, SE) <ul style="list-style-type: none">– Acute vs. chronic graft versus host disease: assessment criteria– Prophylaxis, treatment and care, supportive and complementary